CD274 and neoplasm: Additionally, the IMpower010 trial showed a DFS benefit with atezolizumab versus best supportive care after adjuvant chemotherapy in patients with resected stage II to IIIA NSCLC, with a pronounced benefit in patients whose tumors expressed programmed death ligand-1 (PD-L1) on ≥ 1% of tumor cells [13].